Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin has announced that it has partnered with Clinilabs Drug Development Corporation to carry out its Phase I/IIa clinical trial of CYB003, a proprietary deuterated psilocybin analogue. CYB003 will be the first psilocybin analogue to be evaluated in Phase I/IIa development for the treatment of major depressive disorder (MDD).

Category Press Release
Published in BioSpace

Companies Featured

Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.